Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.32 |
| ▸ | TTR | P02766 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457940 | 0.83 | CYP3A4 (0.35) | TSHRHSD17B10CA1CA2ESR2 | |
| SCHEMBL17112790 | 0.81 | HSD17B1 (0.34) | — | |
| SCHEMBL12491986 | 0.80 | CA12 (0.37) | TSHRCA1CA2 | |
| SCHEMBL22336 | 0.80 | MAOB (0.43) | TSHRCA2 | |
| SCHEMBL15367187 | 0.80 | AR (0.46) | — | |
| SCHEMBL117688 | 0.78 | ENPP2 (0.43) | TSHR | |
| SCHEMBL1277500 | 0.77 | ALDH1A1 (0.38) | TSHR | |
| SCHEMBL2325728 | 0.77 | KCNH2 (0.33) | — | |
| SCHEMBL18706282 | 0.77 | ALDH1A1 (0.42) | TSHRHSD17B10 | |
| SCHEMBL1181137 | 0.76 | ENPP2 (0.41) | TSHRHSD17B10CA1CA2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112341434-B | PI3K/mTOR protein degradation targeting chimera compound and preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-112341434-A | PI3K/mTOR protein degradation targeting chimera compound and preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2021-02-09 | — | — | CN | disclosed |
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2888232-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014029726-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | TP53, RB1, HCCS | TSHR 947/4885HSD17B10 3384/4885CA1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.